SNTB2
Basic information
Region (hg38): 16:69187147-69309052
Previous symbols: [ "SNT2B2", "SNTL", "D16S2531E" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SNTB2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 28 | 28 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 28 | 0 | 0 |
Variants in SNTB2
This is a list of pathogenic ClinVar variants found in the SNTB2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-69187182-G-C | not specified | Uncertain significance (Apr 07, 2023) | ||
16-69187185-A-G | not specified | Uncertain significance (Nov 20, 2024) | ||
16-69187186-C-T | not specified | Uncertain significance (Apr 06, 2024) | ||
16-69187189-C-T | not specified | Uncertain significance (Dec 27, 2023) | ||
16-69187223-G-C | not specified | Uncertain significance (Aug 22, 2023) | ||
16-69187225-C-T | not specified | Uncertain significance (Aug 20, 2024) | ||
16-69187231-C-T | not specified | Uncertain significance (Jan 29, 2024) | ||
16-69187387-C-T | not specified | Uncertain significance (Jan 23, 2024) | ||
16-69187395-G-T | not specified | Uncertain significance (Jun 21, 2023) | ||
16-69187438-T-G | not specified | Uncertain significance (Jul 09, 2021) | ||
16-69187449-A-C | not specified | Uncertain significance (Feb 10, 2022) | ||
16-69187452-C-T | not specified | Uncertain significance (Jan 29, 2024) | ||
16-69187462-C-T | not specified | Uncertain significance (Dec 15, 2023) | ||
16-69187468-G-A | not specified | Uncertain significance (Oct 24, 2024) | ||
16-69187479-G-A | not specified | Uncertain significance (Feb 27, 2024) | ||
16-69187479-G-T | not specified | Uncertain significance (Dec 03, 2024) | ||
16-69187536-G-A | not specified | Uncertain significance (Sep 29, 2023) | ||
16-69187582-C-T | not specified | Uncertain significance (Aug 08, 2024) | ||
16-69187587-C-G | not specified | Uncertain significance (Oct 01, 2024) | ||
16-69187723-C-T | not specified | Uncertain significance (Jan 17, 2024) | ||
16-69245635-A-C | not specified | Uncertain significance (Apr 26, 2023) | ||
16-69245638-A-G | not specified | Uncertain significance (Apr 23, 2024) | ||
16-69245679-C-A | not specified | Uncertain significance (Sep 13, 2023) | ||
16-69245716-G-C | not specified | Uncertain significance (Oct 29, 2024) | ||
16-69245719-C-T | not specified | Uncertain significance (Jan 24, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SNTB2 | protein_coding | protein_coding | ENST00000336278 | 7 | 121924 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.000428 | 0.992 | 125737 | 0 | 11 | 125748 | 0.0000437 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.32 | 156 | 262 | 0.596 | 0.0000136 | 3420 |
Missense in Polyphen | 23 | 60.744 | 0.37864 | 692 | ||
Synonymous | 0.965 | 95 | 108 | 0.882 | 0.00000604 | 1163 |
Loss of Function | 2.36 | 9 | 20.5 | 0.439 | 0.00000118 | 223 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000152 | 0.000152 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000463 | 0.0000462 |
European (Non-Finnish) | 0.0000530 | 0.0000527 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Adapter protein that binds to and probably organizes the subcellular localization of a variety of membrane proteins. May link various receptors to the actin cytoskeleton and the dystrophin glycoprotein complex. May play a role in the regulation of secretory granules via its interaction with PTPRN.;
- Pathway
- Disopyramide Action Pathway;Procainamide (Antiarrhythmic) Action Pathway;Phenytoin (Antiarrhythmic) Action Pathway;Fosphenytoin (Antiarrhythmic) Action Pathway;Bopindolol Action Pathway;Timolol Action Pathway;Carteolol Action Pathway;Bevantolol Action Pathway;Practolol Action Pathway;Dobutamine Action Pathway;Isoprenaline Action Pathway;Arbutamine Action Pathway;Amiodarone Action Pathway;Levobunolol Action Pathway;Metipranolol Action Pathway;Mexiletine Action Pathway;Lidocaine (Antiarrhythmic) Action Pathway;Quinidine Action Pathway;Sotalol Action Pathway;Epinephrine Action Pathway;Betaxolol Action Pathway;Atenolol Action Pathway;Alprenolol Action Pathway;Acebutolol Action Pathway;Muscle/Heart Contraction;Diltiazem Action Pathway;Propranolol Action Pathway;Pindolol Action Pathway;Penbutolol Action Pathway;Oxprenolol Action Pathway;Metoprolol Action Pathway;Esmolol Action Pathway;Bisoprolol Action Pathway;Bupranolol Action Pathway;Nebivolol Action Pathway;Amlodipine Action Pathway;Verapamil Action Pathway;Nitrendipine Action Pathway;Nisoldipine Action Pathway;Nimodipine Action Pathway;Ibutilide Action Pathway;Tocainide Action Pathway;Flecainide Action Pathway;Isradipine Action Pathway;Fosphenytoin (Antiarrhythmic) Metabolism Pathway;Nifedipine Action Pathway;Felodipine Action Pathway;Nadolol Action Pathway;Carvedilol Action Pathway;Labetalol Action Pathway
(Consensus)
Recessive Scores
- pRec
- 0.140
Haploinsufficiency Scores
- pHI
- 0.789
- hipred
- Y
- hipred_score
- 0.694
- ghis
- 0.690
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.673
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Sntb2
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); normal phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- Cellular component
- cytoplasm;microtubule;focal adhesion;dystrophin-associated glycoprotein complex;membrane;transport vesicle membrane;protein-containing complex;synapse
- Molecular function
- RNA binding;actin binding;structural molecule activity;protein binding;calmodulin binding